Previous close | 12.75 |
Open | 13.00 |
Bid | 14.89 x 200 |
Ask | 14.95 x 700 |
Day's range | 12.86 - 14.94 |
52-week range | 8.79 - 32.10 |
Volume | |
Avg. volume | 2,074,254 |
Market cap | 715.805M |
Beta (5Y monthly) | -0.57 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.17 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 13 Dec 2012 |
1y target est | 103.00 |
Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.
Cassava Sciences Inc (NASDAQ:SAVA) stock is trading lower on Wednesday on a heavy session volume of 14.35 million, as per data from Benzinga Pro. The Board of Directors appointed Richard (Rick) Barry as Executive Chairman and the company’s principal executive officer, effective immediately. The company is searching for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company’s Chairman, President, and CEO, who resigned and will remain employed by the Company until September 13, 2024, in
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company’s principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. M